Akèy › Skizofreni › Illinois › Chicago
Etid klinik pou Skizofreni nan Chicago, IL
20 etid pou Skizofreni ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Ap rekriteFaz 1
- Uptown Research Institute, Chicago
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Ap rekriteFaz 3
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Ap rekriteFaz 3
- Neurocrine Clinical Site, Chicago
A Study of Brenipatide in Adult Participants With Schizophrenia
Ap rekriteFaz 2
- Re:Cognition Health - Chicago, Chicago
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Ap rekriteFaz 3
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
52-week Open Label Safety-Tolerability Study
Ap rekriteFaz 3
- Pillar Clinical Research, Chicago
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Ap rekriteFaz 3
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Ap rekriteFaz 1
- Uptown Research Institute, Chicago
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Ap rekriteFaz 2
- Clinical Site, Chicago
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Ap rekriteFaz 3
- Alkermes Investigator Site, Chicago
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Ap rekriteFaz 2
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Ap rekriteFaz 3
- Pillar Clinical Research, Chicago
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Ap rekriteFaz 2
- Uptown Research Institute, Chicago
A Study to Evaluate the Effect of KarXT on Urological Safety
Ap rekriteFaz 4
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
CLOZAPINE Response in Biotype-1
Ap rekriteFaz 4
- University of Chicago, Chicago
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
Ap rekriteEtid obsèvasyon
- University of Chicago Medical Center, Chicago
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Ap rekriteFaz 3
- Neurocrine Clinical Site, Chicago
Randomized Withdrawal Study in Patients With Schizophrenia
Ap rekriteFaz 3
- Vanda Investigational Site, Chicago
Study of ALTO-101 in Patients With Schizophrenia
Ap rekriteFaz 2
- Site 5056, Chicago
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Ap rekriteFaz 3Volontè an sante akeyi
- Reviva site, Chicago
Etid Skizofreni nan lòt vil
- Atlanta, GA22 etid
- Little Rock, AR19 etid
- Hollywood, FL15 etid
- Boston, MA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Hialeah, FL13 etid
- New York City, NY13 etid
- San Diego, CA13 etid
- Garden Grove, CA12 etid
- Germantown, MD11 etid
- Camden, NJ10 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)52 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite42 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Ensifizyans kadyak32 etid
- Kansè kolorektal32 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.